EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Predicting cognitive decline with amyloid‐PET, plasma p‐tau217, Aβ42/40, and p‐tau217/Aβ42 in a community‐based cohort – relevance for clinical trial enrollment

Dario Bachmann iD, Maha Wybitul, Andreas Buchmann, Christoph Gericke, Antje Saake, Sandro Studer, Katrin Rauen, Esmeralda Gruber, Kaj Blennow, Henrik Zetterberg, Roger M Nitsch, Christoph Hock und 2 weitere

Alzheimer's & Dementia · 2025-10 · 21 (10)

DOI: 10.1002/alz.70802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 21.10.2025. Verfasst von Dario Bachmann und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction, Peptide Fragments. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Zurich, Mäxi Foundation, Vontobel Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Identifying at‐risk individuals and selecting sensitive cognitive outcome measures are critical for designing efficient clinical trials targeting early Alzheimer's disease (AD) stages. METHODS We compared amyloid beta (Aβ)‐positron emission tomography (PET), plasma tau phosphorylated at threonine 217 (p‐tau217), Aβ42/40, and p‐tau217/Aβ42‐related decline across neuropsychological and functional measures in 225 individuals (176 cognitively unimpaired (CU), 49 with mild cognitive impairment (MCI). Johnson–Neyman analysis identified the biomarkers, which were used as trial inclusion criteria to estimate sample sizes needed to detect a 30% slowing across cognitive outcomes. RESULTS In the CU, using combined plasma Aβ42/40 and p‐tau217 cut‐offs for eligibility yielded the lowest sample size estimates for a comprehensive multidomain cognitive composite score, whereas sample sizes were higher for all other inclusion criteria based on single biomarkers. In MCI, estimates were substantially lower and less variable across most inclusion criteria and outcome measures. DISCUSSION These findings highlight the need for careful consideration of outcome measures, baseline diagnosis, and inclusion criteria, given their substantial effect on sample size estimation in trials. Highlights Aβ SUVR, plasma p‐tau217, and the p‐tau217/Aβ42 ratio predicted decline across multiple cognitive domains. Using cohort‐specific biomarker cutoffs, sample size estimates were similar for p‐tau217 combined with Aβ42/40 or Aβ SUVR. A multidomain composite best detected AD‐related decline. Outcome measures and eligibility criteria strongly impact sample size estimates, especially in CU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-Peptidestau ProteinsCognitive DysfunctionPeptide FragmentsHumansMalePositron-Emission TomographyFemaleAgedBiomarkersCohort StudiesNeuropsychological TestsPhosphorylationAged, 80 and overAlzheimer DiseaseMiddle Aged

Stichwörter der Autor:innen

blood biomarkersclinical trialscognitioncomposite scorepreclinical Alzheimer's diseasesample size

Substanzen

Amyloid beta-Peptidestau ProteinsBiomarkersPeptide Fragmentsamyloid beta-protein (1-42)

Autor:innen und Institutionen

  • Institute for Regenerative Medicine, University of Zurich, Zurich, Switzerland.
  • Neuroscience Center Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
  • Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated…

ORCID-Profile: Dario Bachmann

Förderung

  • University of Zurich
  • Mäxi Foundation
  • Vontobel Foundation
  • Swiss National Science Foundation
  • the Swedish Research Council
  • Swedish Alzheimer Foundation
  • Hjärnfonden
  • ALF-agreement

Zitieren

APA

Bachmann, D., Wybitul, M., Buchmann, A., Gericke, C., Saake, A., Studer, S., Rauen, K., Gruber, E., Blennow, K., Zetterberg, H., Nitsch, R. M., Hock, C., Treyer, V., & Gietl, A. (2025). Predicting cognitive decline with amyloid‐PET, plasma p‐tau217, Aβ42/40, and p‐tau217/Aβ42 in a community‐based cohort – relevance for clinical trial enrollment. Alzheimer's & Dementia, 21(10). https://doi.org/10.1002/alz.70802

Vancouver

Bachmann D, Wybitul M, Buchmann A, Gericke C, Saake A, Studer S, et al. Predicting cognitive decline with amyloid‐PET, plasma p‐tau217, Aβ42/40, and p‐tau217/Aβ42 in a community‐based cohort – relevance for clinical trial enrollment. Alzheimer's & Dementia. 2025;21(10). doi:10.1002/alz.70802

BibTeX
@article{Bachmann2025,
  author = {Bachmann, Dario and Wybitul, Maha and Buchmann, Andreas and Gericke, Christoph and Saake, Antje and Studer, Sandro and Rauen, Katrin and Gruber, Esmeralda and Blennow, Kaj and Zetterberg, Henrik and Nitsch, Roger M and Hock, Christoph and Treyer, Valerie and Gietl, Anton},
  title = {Predicting cognitive decline with amyloid‐PET, plasma p‐tau217, Aβ42/40, and p‐tau217/Aβ42 in a community‐based cohort – relevance for clinical trial enrollment},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {10},
  doi = {10.1002/alz.70802}
}
Kostenlos starten →